ArticleFrontiers in endocrinology2020

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.

Katharina Jähn-Rickert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.